Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients

The average Adjusted Symptom Score, a new primary efficacy end-point for specific allergen immunotherapy trials

(2011) J.-M. Grouin et al.   CLINICAL AND EXPERIMENTAL ALLERGY

The Health Economics of Allergen Immunotherapy

(2011) Cheryl S. Hankin et al.   IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA

Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen–induced rhinoconjunctivitis

(2011) Alain Didier et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class

(2010) Michael Benninger et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Rinite alérgica: indicadores de qualidade de vida

(2010) Inês Cristina Camelo-Nunes et al.   Jornal Brasileiro de Pneumologia

Implementation of pre-seasonal sublingual immunotherapy with a five-grass pollen tablet during optimal dosage assessment

(2009) F. Horak et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber

(2009) Friedrich Horak et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

(2008) J. Bousquet et al.   ALLERGY

Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis

(2008) Ulrich Wahn et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY